GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (NAS:XCUR) » Definitions » Cash Ratio

Exicure (Exicure) Cash Ratio : 1.63 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Exicure Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Exicure's Cash Ratio for the quarter that ended in Jun. 2023 was 1.63.

Exicure has a Cash Ratio of 1.63. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Exicure's Cash Ratio or its related term are showing as below:

XCUR' s Cash Ratio Range Over the Past 10 Years
Min: 0.61   Med: 3.65   Max: 12.86
Current: 1.63

During the past 7 years, Exicure's highest Cash Ratio was 12.86. The lowest was 0.61. And the median was 3.65.

XCUR's Cash Ratio is ranked worse than
63.85% of 1524 companies
in the Biotechnology industry
Industry Median: 2.85 vs XCUR: 1.63

Exicure Cash Ratio Historical Data

The historical data trend for Exicure's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exicure Cash Ratio Chart

Exicure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Ratio
Get a 7-Day Free Trial 12.86 3.56 5.98 1.15 5.23

Exicure Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.13 0.61 5.23 3.65 1.63

Competitive Comparison of Exicure's Cash Ratio

For the Biotechnology subindustry, Exicure's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exicure's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exicure's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Exicure's Cash Ratio falls into.



Exicure Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Exicure's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=8.577/1.639
=5.23

Exicure's Cash Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash Ratio (Q: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=2.335/1.431
=1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exicure  (NAS:XCUR) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Exicure Cash Ratio Related Terms

Thank you for viewing the detailed overview of Exicure's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exicure (Exicure) Business Description

Traded in Other Exchanges
Address
2430 N. Halsted Street, Suite 410, Chicago, IL, USA, 60614
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Executives
Minhee Eom director 2430 N. HALSTED ST., CHICAGO IL 60614
Dongho Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Hyuk Joon Ko director 2430 N. HALSTED ST., CHICAGO IL 60614
Hojoon Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Dgp Co., Ltd. 10 percent owner 23, GEURINTEKEU-RO, YEONGGWANG-EUP, YEONGGWANG-GUN, JEOLLANAM-DO M5 57024
Jung Sang Kim director, officer: Chief Executive Officer, CFO 46-31 CHEONGRO 3 GIL, GEUMSUNG-MYEON, UEISUNG-GUN, GYEONGSANGBUK-DO M5 37357
Josh Miller director, officer: Chief Executive Officer, CFO 2430 N. HALSTED ST., CHICAGO IL 60614
Jiyoung Hwang director C/O EXICURE, INC., 2430 N. HALSTED ST., CHICAGO IL 60614
Cheolho Jo director 2430 N. HALSTED ST., CHICAGO IL 60614
Seung Soo Shin director 2430 N. HALSTED ST., CHICAGO IL 60614
Hyukku Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Sung Uh Kang Paul director 2430 N. HALSTED ST., CHICAGO IL 60614
Changil Ahn director 2430 N. HALSTED ST., CHICAGO IL 60614
Cbi Usa, Inc. 10 percent owner 3000 WESTERN AVENUE, SUITE 400, SEATTLE WA 98121
Bali Muralidhar director C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077

Exicure (Exicure) Headlines

From GuruFocus